Enterprise Value
59.73M
Cash
139M
Avg Qtr Burn
-16.31M
Short % of Float
2.14%
Insider Ownership
22.05%
Institutional Own.
17.93%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CT-0508 (HER2) combo w/ Pembrolizumab Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CT-0508 (HER2) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CT-0525 (HER2) Details Solid tumor/s, Cancer | IND Submission | |
Vicineum™ Details Bladder cancer, Cancer | Failed Discontinued | |
Vicineum™ Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued |